| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Bopindolol (INN) is a beta blocker. It is an ester which acts as a prodrug for "pindolol":http://drugbank.ca/drugs/DB00960. |
| Indication |
For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation. |
| Pharmacology |
Bopindolol is a prodrug of pindolol. Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| External Links |
|
|